Pfizer begins study of potential Covid-19 therapy Paxlovid in children
The Phase 2/3 EPIC-PEDS study is designed to enrol around 140 paediatric participants, aged below 18 years of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Mar 22
The Phase 2/3 EPIC-PEDS study is designed to enrol around 140 paediatric participants, aged below 18 years of…
10 Mar 22
Nitroglycerin sublingual tablet is used to relieve episodes of chest pain, called angina, in people with coronary artery…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Mar 22
The companies will advance the development of FixVac and Libtayo to treat advanced NSCLC, expanding their existing partnership…
09 Mar 22
Novartis can access Voyager’s AAV capsids for use in therapies for three central nervous system diseases, with options…
08 Mar 22
The company has also announced its public health strategy, which targets the prevention of infectious diseases by advancing…
08 Mar 22
The new site will use new technologies to enhance the efficiency and capability to produce a wide range…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Mar 22
How the pandemic changed vaccine production forever with governments, industries and suppliers all working together.
07 Mar 22
In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy showed superior outcomes compared to platinum-doublet chemotherapy…
07 Mar 22
Discovered at Zydus Research Centre, Oxemia is a differentiated HIF-PH Inhibitor, the first alternative to injectable erythropoietin-stimulating agents…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 22
The new Enterprise Solutions Hub will support the US, Canada and Latin America, offering services similar to its…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates